Bearish Risk: US Tariffs Hit Patented Drugs; SUNPHARMA Faces Headwinds

The US has implemented tariffs of up to 100% on patented drugs, specifically excluding generics and biosimilars. This policy directly targets specialty pharmaceutical players, creating a challenging environment for Indian companies with significant exposure to this segment in the US market.

This development is crucial for Indian pharma as the US is a primary export market. While generics have been a stronghold, many Indian firms are expanding into specialty and patented drug segments for higher margins. These tariffs directly threaten the profitability and growth prospects of these high-value segments, potentially impacting overall sector earnings.

Indian specialty pharma companies, particularly those with a strong patented drug portfolio in the US, are likely to face negative pressure. SUNPHARMA is explicitly mentioned as facing the steepest risk. Contract Development and Manufacturing Organizations (CDMOs) like Sai Lifesciences might experience selective impact depending on their client base's exposure to patented drugs, leading to potential order reductions or pricing pressures.

Traders should monitor company-specific disclosures regarding US revenue breakdown and exposure to patented drugs. Watch for management commentary on mitigation strategies, potential shifts in product pipelines, and any renegotiations with US partners. The extent of earnings revisions by analysts for affected companies will also be a key indicator.

• •US imposed up to 100% tariffs on patented drugs.
• •Generics and biosimilars are spared from these tariffs.
• •India’s speciality pharma players are exposed to this risk.
• •Sun Pharma faces the steepest risk.
• •CDMOs like Sai Lifesciences may see selective impact.
• •Analysts at Jefferies and Nomura expect modest to mid-single-digit earnings pressure.